Dr Peter McCullough: Spike protein detox protocol explained (2026)

Dr. McCullough explained that the spike protein is an engineered, synthetic molecule roughly 1,200 amino acids long and resistant to degradation by the body’s normal proteases. He described how the protein was modified in laboratory settings (notably at the Wuhan Institute of Virology) to tightly bind to the ACE2 receptor, which is found throughout the body—in the lungs, heart, endothelium, kidneys, and brain. Because this receptor regulates angiotensin metabolism, older individuals with fewer ACE2 sites catabolize the spike less efficiently, leading to worse outcomes. Whether introduced by infection or by genetic‑code‑based vaccines, McCullough asserted, the persistent spike damages tissues directly and through chronic inflammation, micro‑clotting, and autoimmune cross‑reactivity.

He cited more than 300 papers documenting spike deposits in the heart, brain, and vascular tissue, relating these findings to post‑vaccine myocarditis, strokes, and clotting disorders. A chief diagnostic step, he said, is LabCorp’s quantitative anti‑spike antibody test run on the Roche‑Elecsys system; titers <1,000 U/mL suggest low risk, whereas high persistent titers (>10,000 U/mL) imply continued spike stimulation. Combined cardiac markers, such as troponin, BNP, galectin‑3, and D‑dimer, help clinicians assess myocardial inflammation and microthrombosis.

McCullough emphasized certain non‑pharmaceutical interventions to “mobilize and clear” the protein: regular sweating (via exercise, outdoor heat, or infrared sauna) to eliminate spike and residual mRNA through skin and sweat glands, and hyperbaric oxygen therapy to enhance oxygenation and possibly alter spike conformation for clearance. He also endorsed modalities that improve micro‑circulation, such as pulsed‑electromagnetic‑field (PEMF) or Beamer devices.

The central focus was the McCullough Protocol Base Spike Detoxification,™ comprising three natural compounds shown in preclinical research to degrade or neutralize spike protein:

1. Nattokinase (2,000–8,000 fibrinolytic units per dose) – an enzyme from fermented soy that dissolves fibrin and spike aggregates;
2. Bromelain (500 mg) – pineapple‑stem protease with anticoagulant and anti‑inflammatory effects;
3. Curcumin (500–1,000 mg, enhanced with piperine or liposomal form) – turmeric’s active polyphenol supporting inflammation resolution and hepatic detoxification.

Related: Nattokinase, Bromelain and Curcumin from The Wellness Company

Taken twice daily on an empty stomach for 9–12 months (longer for heavily vaccinated or long‑COVID patients), this triad forms the backbone of The Wellness Company’s Ultimate Spike Detox supplement. McCullough reported thousands of clinical users and minimal adverse events, warning only of potential bleeding when combined with prescription anticoagulants. Adjunctive options include N‑acetylcysteine to support glutathione, hydroxychloroquine for autoimmune suppression, and short courses of ivermectin or longer-term colchicine when indicated.

Concluding, McCullough urged practitioners to recognize the persistent spike protein as the driver of post‑COVID syndromes and “vaccine injury,” and called for empirical, integrative solutions in the absence of federal research funding. Gaeta summarized the key message: effective recovery requires clearing the spike through enzymes, circulation, oxygenation, and sweating—using natural, accessible means rather than endless pharmaceutical management.

Source: https://www.americaoutloud.news/dr-mcculloughs-spike-protein-detox-protocol-explained/

Internist and Cardiologist Dr. Bruce Boros

Medical Specialist Witnesses Powerful Effect of Ivermectin in Acute Illness and Wonderful Recoveries from Long-COVID with Ultimate Spike Detox

Dr. Bruce Boros is a top shelf internist and cardiologist who brought modern cardiology to the Florida Keys. His stories of handling acute COVID-19 in acutely ill patients who had nowhere to go are amazing because he had first hand examination and chest CT evidence of rapid resolution with high dose ivermectin. He instinctively knew high-risk seniors who frequent the coral cay archipelago needed early multidrug treatment.

Later in the pandemic, Boros who is age 75 and unvaccinated, felt himself like so many of his patients, that he was suffering from long-COVID syndrome. He describes loss of mental clarify, a fogginess, fatigue and lack of energy. He mentioned to his wife he was concerned about developing cognitive decline that could threaten his vibrant medical practice.

After a conversation we had about the science of McCullough Protocol Base Spike Detoxification, Dr. Boros put himself on Ultimate Spike Detox from The Wellness Company. He was already on a robust supplement regimen and had original treatment with ivermectin. With that base, he was set up for success with the higher dose and more intensive Spike formula. He was thrilled to report his symptoms have resolved in weeks and he is seeing similar progress with his long-COVID patients.

Dr. Peter McCullough suggests that a detoxification protocol should be followed for at least a year to prevent the recurrence of symptoms, which might occur due to reinfection or possibly from shedding. He indicates that if these products, such as Ultimate Spike Detox or Spike Support, are well tolerated, they can be continued indefinitely.

Source: https://petermcculloughmd.substack.com/p/profile-in-valor-internist-and-cardiologist

References:

1. The Wellness Company – “Base Spike Detoxification: The Spike Protein Detoxification Protocol You Need to Know,” Aug 25 2023.
2. The Wellness Company – “Why Ultimate Spike Detox?” Nov 8 2024.
3. Washington Guardian – “Ultimate Spike Detox: The Wellness Company’s Signature Formula for Cellular Defense,” Jan 2 2025.
4. Transcript of Gaeta Institute Mondays with Michael episode #304 featuring Dr. Peter McCullough, Feb 23, 2026.
5. McCullough P.A., et al. “Clinical Rationale for SARS‑CoV‑2 Base Spike Protein Detoxification in Post‑COVID‑19 and Vaccine Injury Syndromes,” Journal of American Physicians and Surgeons 28(3):90‑93 (2023).